Scientific Background
More than 10% of the human proteome contains PRM-binding domains – a class of protein-domains specialized in the recognition of proline-rich motifs.
These domains are involved in a multitude of pathologies, such as cancer, Alzheimer’s and other neurodegenerative diseases, cardiovascular diseases, immune-meditated disorders, etc.
However, they are so far considered as “undruggable”, making peptidomimetic and small molecule competitors of PRM urgently needed.
